Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Fulcrum Therapeutics, Inc. | fulc-ex322_6.htm |
| EX-32.1 - EX-32.1 - Fulcrum Therapeutics, Inc. | fulc-ex321_12.htm |
| EX-31.2 - EX-31.2 - Fulcrum Therapeutics, Inc. | fulc-ex312_8.htm |
| EX-31.1 - EX-31.1 - Fulcrum Therapeutics, Inc. | fulc-ex311_9.htm |
| EX-21.1 - EX-21.1 - Fulcrum Therapeutics, Inc. | fulc-ex211_10.htm |
| EX-10.16 - EX-10.16 - Fulcrum Therapeutics, Inc. | fulc-ex1016_279.htm |
| EX-10.9 - EX-10.9 - Fulcrum Therapeutics, Inc. | fulc-ex109_280.htm |
| 10-K - 10-K - Fulcrum Therapeutics, Inc. | fulc-10k_20201231.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
1. |
Registration Statement (Form S-8 No. 333-233452) pertaining to the 2016 Stock Incentive Plan, as amended, 2019 Stock Incentive Plan, and 2019 Employee Stock Purchase Plan of Fulcrum Therapeutics, Inc., |
|
|
2. |
Registration Statement (Form S-8 No. 333-236910) pertaining to the 2019 Stock Incentive Plan and 2019 Employee Stock Purchase Plan of Fulcrum Therapeutics, Inc., |
|
|
3. |
Registration Statement (Form S-1 No. 333-239353) and related Prospectus of Fulcrum Therapeutics, Inc.; and, |
|
|
4. |
Registration Statement (Form S-3 No. 333-244136) and related Prospectus of Fulcrum Therapeutics, Inc.; |
of our report dated March 4, 2021, with respect to the consolidated financial statements of Fulcrum Therapeutics, Inc. included in this Annual Report (Form 10-K) of Fulcrum Therapeutics, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 4, 2021